Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

© 2014 Elsevier Inc. All rights reserved.Impaired signal transmission at the neuromuscular junction results in fatigable muscle weakness that may derive from genetic mutations or be acquired due to an autoimmune response. The number of proteins associated with genetic forms of myasthenia is steadily increasing, and includes proteins directly involved in signal transfer or involved in the organization and structure of this synapse. An understanding of the molecular mechanisms allows alternative treatment strategies to be applied appropriately. The acquired myasthenias make up the majority of cases with autoantibodies directed against the acetylcholine receptor, but here too the number of identified targets for autoimmune attack is growing, with known pathogenic antibodies directed against the presynaptic voltage-gated calcium channels and the postsynaptic protein, MuSK. Treatment strategies again vary according to the antigenic target.

Original publication

DOI

10.1016/B978-0-12-801238-3.05603-8

Type

Chapter

Book title

Reference Module in Biomedical Research

Publication Date

15/12/2014